Growth hormone replacement normalizes impaired fibrinolysis: New insights into endothelial dysfunction in patients with hypopituitarism and growth hormone deficiency

Growth Hormone and IGF Research

Volumn 23, Issue 6, 2013, Pages 243-248

  Miljic, D ^a   Miljic, P ^a   Doknic, M ^a   Pekic, S ^a   Stojanovic, M ^a   Cvijovic, G ^a   Micic, D ^a   Popovic, V ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Endothelial t PA; Fibrinolysis; GH deficiency; GH replacement; Vascular risk in hypopituitarism

Indexed keywords

GROWTH HORMONE; INSULIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; FIBRINOLYSIS; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; INSULIN SENSITIVITY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SECRETION; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VEIN OCCLUSION;

ENDOTHELIAL T-PA; FIBRINOLYSIS; GH DEFICIENCY; GH REPLACEMENT; VASCULAR RISK IN HYPOPITUITARISM;

ADULT; CASE-CONTROL STUDIES; DWARFISM, PITUITARY; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84886099931     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2013.08.005     Document Type: Article

References (49)

1. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336:285-288.
2. Bates A.S., Van't Hoff W., Jones P.J., Clayton R.N. The effect of hypopituitarism on life expectancy. J. Clin. Endocrinol. Metab. 1996, 81:1169-1172.
3. Bulow B., Hagmar L., Mikoczy Z., et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin. Endocrinol. 1997, 46:75-81.
4. Tomilson J.W., Holden N., Hills R.K., et al. Association between premature mortality and hypopituitarism. Lancet 2001, 357:425-431.
5. Evans L.M., Davies J., Anderson R., et al. The effect of growth hormone replacement therapy on endothelial dysfunction and oxidative stress in adult growth hormone deficiency. Eur. J. Endocrinol. 2000, 142:254-262.
6. Evans L.M., Davies J.S., Goodfellow J., et al. Endothelial dysfunction in hypopituitary adults with growth hormone deficiency. Clin. Endocrinol. 1999, 50:457-464.
7. Pfeifer M., Verhovec R., Zizek B., et al. Growth hormone(GH)treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 1999, 84:453-457.
8. Berson-Chazot F., Serusclat A., Kalfallah Y., et al. Decrease in carotid intima-media thickness after one year growth hormone (GH) treatment in adults with GH deficiency. J. Clin. Endocrinol. Metab. 1999, 84:1329-1333.
9. Rosen T., Eden S., Larson G., Wilhelmsen L., Bengtsson B.A. Cardiovascular risk factors in growth hormone deficient adults. Acta Endocrinol. 1993, 129:195-200.
10. Beshyah S.A., Johntson D.G. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin. Endocrinol. 1999, 50:1-15.
11. Kvasnicka J., Marek J., Kvasnicka T., et al. Increase of adhesion molecules, fibrinogen, type-1 plasminogen activator inhibitor and orosomucoid in growth hormone deficient adults and their modulation by recombinant human GH replacement. Clin. Endocrinol. 2000, 52:543-548.
12. Sartorio A., Cattaneo M., Bucciarelli P., et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Exp. Clin. Endocrinol. Diabetes 2000, 108:486-492.
13. Sesmilo G., Biller B.M., Lievadot J., Hayden D., Hanson G., Rifai N., Klibanski A. Effects of growth hormone administration on inflammation and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled, clinical trial. Ann. Intern. Med. 2000, 133:111-122.
14. Sesmilo G., Biller B.M., Lievadot J., Hayden D., Hanson G., Rifai N., Klibanski A. Effects of growth hormone(GH)administration on homocysteine levels in men with GH deficiency: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2001, 86:1518-1524.
15. Johansson J.-O., Landin K., Johansson G., Tengborn L., Bengtsson B.-A. Long treatment with growth hormone decreases plasminogen activator inhibitor and tissue plasminogen activator in growth hormone deficient adults. Thromb. Haemost. 1996, 76:422-428.
16. Johansson J.-O., Landin K., Tengborn L., Rosen T., Bengtsson B.-A. High fibrinogen and plasminogen activator inhibitor activity in growth hormone deficient adults. Arterioscler. Thromb. 1994, 14:434-437.
17. Devin J.K., Blevins L.S., Verity D.K., Chen Q., Bloodworth J.R., Covington J., Vaughan D.E. Markedly impaired fibrinolytic balance contributes to cardiovascular risk in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 2007, 92:3633-3639.
18. Di Minno M.N., Palmieri V., Lombardi G., Pezzulo S., Cirillo F., Di Somma C., Valle D., Di Minno G. Lack of change in insulin levels as a biological marker of PAI-1 lowering in GH-deficient adults on r-HGH replacement therapy. Thromb. Res. 2009, 124:711-713.
19. Miljic D., Miljic P., Doknic M., Pekic S., Djurovic M., Colovic M., Popovic V. Changes in prothrombin and activated partial thromboplastin time during replacement therapy with human recombinant growth hormone in growth hormone deficient adults. Hormones (Athens) 2006, 5:187-191.
20. Gomez J.M., Sahun M., Vila R., Domenech P., Catalina P., Soler J., Badimon L. Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function inn hypopituitary adults with growth hormone deficiency. Clin. Endocrinol. 2006, 64:632-639.
21. Lanes R., Paoli M., Carrillo E., Villaroel O., Palacios A. Peripheral inflammatory and fibrinolytic makers in adolescents with growth hormone deficiency: a relation to postprandial dyslipidemia. J. Pediatr. 2004, 14:657-661.
22. Can ete R., Valle M., Martos R., Sánchez-Carrión A., Can ete M.D., van Donkelaar E.L. Short-term effects of GH treatment on coagulation, fibrinolysis, inflammation biomarkers, and insulin resistance status in prepubertal children with GH deficiency. Eur. J. Endocrinol. 2012, 167:255-260.
23. Jern S., Wall U., Bergbrant A., Selin-Sjogren L., Jern C. Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension. Arterioscler. Thromb. Vasc. Biol. 1997, 17:3376-3383.
24. Parmer R.J., Mahata M., Mahata S., Sebald M.T., O'Connor D.T., Miles L.A. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. J. Biol. Chem. 1997, 272:1976-1982.
25. Ho K. GH deficiency consensus workshop participants. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society and Endocrine Society of Australia. Eur. J. Endocrinol. 2007, 157:695-700.
26. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R., Vance M.E. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96:1587-1609.
27. Micic D., Cvijovic G., Doknic M., Kendreski A., Popovic V. Effect of 12months of recombinant human growth hormone replacement therapy on insulin sensitivity in GH-deficient adults as determined by different methods. J. Postgrad. Med. 2002, 48:260-265.
28. Laffan M., Manning R. Investigation of thrombotic tendency. Dacie and Lewis Practical Haematology 2006, 441-463. Churchil Livingstone Elsevier. 10th edition. S.M. Lewis, B.J. Bain, I. Bates (Eds.).
29. Syrjälä M.T., Krusius T., Petäjä J., Vahtera E., Rasi V. Venous occlusion test: assessment of fibrinolytic capacity by D-dimer latex agglutination test. Fibrinolysis 1993, 7:41-45.
30. Gram J., Jespersen J., Kluf C., Rijken D.C. On the usefulness of fibrinolytic variables in the characterization of a risk group for myocardial reinfarction. Acta. Med. Scand. 1987, 221:149-153.
31. Hamsten A., Wiman B., de Faire V., Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 1985, 313:1557-1563.
32. Meade T.W., Ruddock V., Stirling Y., Chakrabarti R., Miller G.J. Fibrinolytic activity, clotting factors and long term incidence of ischemic heart disease in the Nothwick Park Heart Study. Lancet 1993, 342:1076-1079.
33. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. European Concentrated Action on Thrombosis and Disabilities Angina Pectoris Study Group. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N. Engl. J. Med. 1995, 332:635-641.
34. Folson A.R., Aleksic C.N., Park E., Salomaa V., Juneja H., Wu K.K. Prospective study of fibrinolytic factors and incident coronary disease: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler. Thromb. Vasc. Biol. 2001, 21:611-617.
35. Loskutoff D.J., Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Atheroscl. Thromb. Vasc. Diab. 1998, 18:1-6.
36. Vaughan D.E. Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease. J. Investig. Med. 1998, 46:370-376.
37. Padayatty S.J., Orme S., Zenobi P.D., Stickel M.H., Belchez P.E., Grant P.J. The effects of insulin like growth factor-1 on plasminogen activator inhibitor-1 activity, synthesis and secretion: results from in vitro and in vivo studies. Thromb. Hemost. 1993, 70:1009-1013.
38. Boger R.H., Skamira C., Bode-Boger S.M., Brabant G., von zur Muhlen A., Frolich J.C. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J. Clin. Invest. 1996, 98:2706-2713.
39. Wickman A., Jonsdottir I.H., Bergstrom G., Hedin L. GH and IGF-1 regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. Eur. J. Endocrinol. 2002, 147:523-533.
40. Napoli R., Guardasole V., Angelini V., D'Amico F., Zarra E., Matarazzo M., Sacca L. Acute effects of growth hormone on vascular function in human subjects in human subjects. J. Clin. Endocrinol. Metab. 2003, 88:2817-2820.
41. Christ E.R., Chowienczyk P.J., Sonksen P.H., Russel-Jones D.L. Growth hormone replacement therapy in adults with growth hormone deficiency improves vascular reactivity. Clin. Endocrinol. 1999, 51:21-25.
42. Katoh M., Egashira K., Mitsui T., Cishima S., Takeshita A., Narita H. Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis. J. Mol. Cell. Cardiol. 2000, 32:73-83.
43. Zeng G., Nystrom F.H., Ravichndran L.V., Cong L.N., Kirby M., Mostowski H., Quon M.J. Role for insulin receptor, PI3-kinase and Akt in insulin signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000, 101:139-154.
44. Thum T., Tsikas D., Frolich J.C., Borlak J. Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line. FEBS Lett. 2003, 555:567-571.
45. Buber P., Singh K.P., Arora S., Bansal D.D. Effects of growth hormone on fibrinolytic system in rat. Indian J. Exp. Biol. 1998, 36:514-516.
46. Borkenstain M., Muntean W. Effects of growth hormone on the factor VIII complex in patients with growth hormone deficiency. Metabolism 1984, 12:1065-1067.
47. Prowse C.V., Dow R.C., Fink G. A hypothalamic-pituitary system that stimulates the release of plasminogen activation in the rat. Brain Res. 1984, 299:133-138.
48. Peacey S.R., Wright D., Aye M., Moisey R. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism. Clin. Endocrinol. 2012, 77:94-98.
49. Hoetzer G.L., Stauffer B.L., Greiner J.J., Casas Y., Smith D.T., Desouza C.A. Influence of oral contraceptive use in endothelial t-PA release in healthy premenopausal women. Am. J. Physiol. Endocrinol. Metab. 2003, 284:90-95.